| Project/Area Number |
20590993
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Neurology
|
|---|
| Research Institution | Gifu University |
|---|
Principal Investigator |
INUZUKA Takashi Gifu University, 医学系研究科, 教授 (50184734)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOZUMI Isao 岐阜大学, 医学系研究科, 准教授 (20242430)
TANAKA Yuji 岐阜大学, 医学系研究科, 助教 (70377654)
KIMURA Akio 岐阜大学, 医学系研究科, 助教 (00362161)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2008: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | プロテオミクス / 抗筋抗体 / 炎症性筋炎 / バイオマーカー / myosin-binding protein / pyruvate kinase isozyme / LC-MS / MSシステム / 二次元ブロット / 解糖系酵素 / 質量分析 |
|---|
| Research Abstract |
We identified two novel antibodies against muscle-specific components in sera of idiopathic inflammatory myopathies (IIMs) patients by proteomic analysis. These target antigens were myosin-binding protein C (MyBP C) and pyruvate kinase isozyme M1/M2 (PK M1/M2). MyBP C belongs to the immunoglobulin superfamily. PK catalyzes the conversion of phosphoenolpyruvate with regeneration of ATPs. Both molecules have been reported as possible myositogenic antigen for experimental autoimmune polymyositis.
The number of patients with the anti- MyBP C antibody was significantly higher among the IIM patients (9 of 10) than among the healthy control (1 of 10) and myotonic dystrophy (MyD) patients (5 of 11). The number of patients with the anti-PK M1/M2 antibody was significantly higher among the IIM patients (5 of 10) than among the healthy control (0 of 10) and myotonic dystrophy (MyD) patients (2 of 11). The sensitivity of this combination assay for diagnosis IIM was 50% and specificity was 80%. The sensitivity of this combination assay for diagnosis polymyositis was 71% and specificity was 92%. Therefore we propose that this combination assay is a candidate for further exploration as a diagnostic marker of IIM, particularly polymyositis.
To clarify the pathogenic roles of anti- MyBP C and PK M1/M2 antibodies in IIM, we must perform more experiments such as using animal models in which these antibodies are passively administrated.
|
